<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med Genet</journal-id><journal-title>BMC Medical Genetics</journal-title><issn pub-type="epub">1471-2350</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2350-7-30</article-id><article-id pub-id-type="pmid">16571112</article-id><article-id pub-id-type="doi">10.1186/1471-2350-7-30</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>N</italic>-<italic>acetyltransferase 2 </italic>(<italic>NAT2</italic>) gene polymorphisms in Parkinson's disease</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Borlak</surname><given-names>Juergen</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>borlak@item.fraunhofer.de</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Reamon-Buettner</surname><given-names>Stella Marie</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>reamon-buettner@item.fraunhofer.de</email></contrib></contrib-group><aff id="I1"><label>1</label>Drug Research and Medical Biotechnology, Fraunhofer Institute of Toxicology and Experimental Medicine, Nikolai-Fuchs-Strasse 1, 30625 Hannover, Germany</aff><aff id="I2"><label>2</label>Chair in Pharmaco-and Toxicogenomics, Center of Pharmacology and Toxicology, Medical School Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>29</day><month>3</month><year>2006</year></pub-date><volume>7</volume><fpage>30</fpage><lpage>30</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/7/30"/><history><date date-type="received"><day>15</day><month>7</month><year>2005</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2006</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2006 Borlak and Reamon-Buettner; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Borlak and Reamon-Buettner; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Borlak Juergen borlak@item.fraunhofer.de </dc:author><dc:title> N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease </dc:title><dc:date>2006</dc:date><dcterms:bibliographicCitation>BMC Medical Genetics 7(1): 30-. (2006)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2350(2006)7:1&#x0003c;30&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2350</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Parkinson's disease (PD) is a movement disorder caused by the degeneration of dopaminergic neurons in the substantia nigra of the midbrain. The molecular basis of this neural death is unknown, but genetic predisposition and environmental factors may cause the disease. Sequence variations in <italic>N-acetyltransferase 2 </italic>(<italic>NAT2</italic>) gene leading to slow acetylation process have been associated with PD, but results are contradictory.</p></sec><sec sec-type="methods"><title>Methods</title><p>We analyzed three <italic>NAT2 </italic>genetic variations, c.481C&#x0003e;T, c.590G&#x0003e;A (p.R197Q) and c.857G&#x0003e;A (p.G286E), which are known to result in a slow acetylator phenotype. Using validated PCR-RFLP assays, we genotyped 243 healthy unrelated Caucasian control subjects and 124 PD patients for these genetic variations. Further, we have undertaken a systematic review of <italic>NAT2 </italic>studies on PD and we incorporated our results in a meta-analysis consisting of 10 studies, 1,206 PD patients and 1,619 control subjects.</p></sec><sec><title>Results</title><p>Overall, we did not find significant differences in polymorphic acetylation genotypes in PD and control subjects. In the meta-analysis of slow acetylators from 10 studies and representing 604/1206 PD vs. 732/1619 control subjects, a marginally significant odds ratio (OR) of 1.32 (95% CI 1.12&#x02013;1.54, p &#x0003c; 0.05) was obtained. Re-analysis of the data to exclude the only two studies showing positive association of slow acetylators to PD, resulted in a non-significant OR (1.07, 95% CI 0.9&#x02013;1.28). Furthermore, meta-analysis of studies for c.590G&#x0003e;A, where both allele and genotype frequencies in PD vs. control subjects were analyzed, did not give significant summary odds ratios as well.</p></sec><sec><title>Conclusion</title><p>We found little evidence for differences in polymorphic acetylation genotypes in PD and control subjects. Results of the meta-analyses did not also provide conclusive evidence for an overall association of <italic>NAT2 </italic>slow acetylator genotypes to PD.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Parkinson's disease (PD, MIM #16860) is a progressive neurodegenerative disorder characterized by resting tremor, muscular rigidity, bradykinesia (slowness of movement), postural instability, and pathologically, the presence of Lewy bodies. This movement disorder is caused by a deficiency of the neurotransmitter dopamine in the striatum of the brain, as a result of degenerating nigrostriatal dopamine neurons. The molecular basis of this neural death is unknown, but may be caused by genetic predisposition and gene environmental interactions, including exposure to pesticides, herbicides and neurotoxins [<xref ref-type="bibr" rid="B1">1</xref>]. For instance, rare pathogenic mutations and gene interactions in <italic>&#x003b1;-synuclein</italic>, <italic>parkin </italic>and <italic>ubiquitin carboxy-terminal hydrolase LI (UCHL1) </italic>have been implicated in PD [<xref ref-type="bibr" rid="B2">2</xref>]. A collaborative pooled analysis of 11 published studies of the <italic>UCHL1 </italic>p.S18Y variant involving 1,970 PD cases and 2,224 unrelated controls, confirmed an inverse association between this variant and PD particularly in younger subjects [<xref ref-type="bibr" rid="B3">3</xref>]. Furthermore, neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and amine-related neurotoxins are proposed to be among the environmental factors, killing selectively dopaminergic neurons over a long period of time [<xref ref-type="bibr" rid="B4">4</xref>].</p><p>The <italic>N</italic>-acetyltransferases (NAT; E.C.2.3.1.5) are involved in the metabolism of drugs and environmental toxins. They catalyze the acetyltransfer from acetylcoenzyme A to an aromatic amine, heterocyclic amine or hydrazine compound. Sequence variations in the human <italic>NAT1 </italic>(MIM# 108345) and <italic>NAT2 </italic>(MIM # 243400) result in the production of NAT proteins with variable enzyme activity or stability, leading to slow or rapid acetylation. Therefore, genetic polymorphisms in <italic>NAT1 </italic>and <italic>NAT2 </italic>have been associated with drug-induced toxicities and disease (see reviews [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]).</p><p>Several association studies have been undertaken on <italic>NAT2 </italic>sequence variations and Parkinson's disease, but results are conflicting [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. Some of these, report on strong associations between slow acetylator genotypes of <italic>NAT2 </italic>with PD in general or with early onset PD [<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B18">18</xref>]. Slow acetylation may lead to insufficient detoxification of neurotoxins inducing PD, but the mechanism remains speculative. Recently, a study showed that intrastriatal 6-hydroxydopamine (6-OHDA) treatment of NAT2 slow acetylator rats led to decrease of striatal dopamine levels as compared to identical treatment of NAT2 rapid acetylator [<xref ref-type="bibr" rid="B21">21</xref>]. Intrastriatal 6-OHDA treatment in rats results in progressive dopaminergic nigral cell loss and constitutes an animal model for PD. To help clarify further the role of <italic>NAT2 </italic>acetylation genotypes in PD, we determined the <italic>NAT2 </italic>genotypes in unrelated PD patients and control healthy individuals of Caucasian origin focusing on three sequence variations, namely c.481C&#x0003e;T, c.590G&#x0003e;A, c.857G&#x0003e;A. We have also undertaken a systematic review of <italic>NAT2 </italic>studies on PD and we incorporated our present results in a meta-analysis consisting of 10 studies, 1,206 PD patients and 1,619 control subjects.</p><p>.</p></sec><sec sec-type="methods"><title>Methods</title><p>Informed consent blood samples were kindly provided by Dr. C.A.D Smith of the Imperial Cancer Research Fund Laboratory of the Ninewell's Hospital in Dundee, U.K. In addition, JB has obtained approval to conduct genetic studies involving human materials from the Medical School of Hannover. All blood samples were obtained from randomly selected, unrelated Caucasian individuals. Using standard PCR-RFLP assay protocols, we employed the restriction enzymes <italic>Kpn</italic>I, <italic>Taq</italic>I and <italic>Bam</italic>HI to distinguish <italic>NAT2 </italic>variations c.481C&#x0003e;T (p.161L, dbSNP rs1799929), c.590G&#x0003e;A (p.R197Q, dbSNP rs1799930) and c.857G&#x0003e;A (p.G286E, dbSNP rs1799931), respectively. On the basis of these <italic>NAT2 </italic>variations, we genotyped 243 healthy unrelated Caucasian control subjects and 124 patients with Parkinson's disease (PD). The reference allele (<italic>NAT2*4</italic>) contains all three restriction sites, thus the identification of homo- and heterozygous carriers could easily be ascertained. In accordance with the human <italic>NAT2 </italic>nomenclature <ext-link ext-link-type="uri" xlink:href="http://louisville.edu/medschool/pharmacology/NAT.html"/>, allele <italic>NAT2*4 </italic>refers to <italic>NAT2 </italic>reference sequence (Genbank accession <ext-link ext-link-type="gen" xlink:href="X14672">X14672</ext-link>). The <italic>NAT2*4 </italic>allele acts dominantly to result in rapid acetylation, and the presence of c.481C&#x0003e;T, c.590G&#x0003e;A, c.857G&#x0003e;A would lead to slow acetylation [<xref ref-type="bibr" rid="B22">22</xref>]. Therefore, for the determination of acetylator status, we classified those possessing at least two mutant alleles as slow acetylators. However, the acetylation status for the synonymous variation c.481C&#x0003e;T is not clear as this is also associated with allele <italic>NAT2*12C </italic>which is actually a rapid allele [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The confidence intervals for the percentages in our original study were computed according to Pearson-Clopper, whereas confidence intervals for the odds ratios were computed assuming asymptotic log normality. Meta-analysis was performed using the package rmeta of the R-Project [<xref ref-type="bibr" rid="B23">23</xref>]. The Mantel-Haenszel procedure meta.MH was applied to analyze the odds ratios of the studies, the Mantel-Haenszel summary, and Woolf's test for heterogeneity. The 95 % confidence intervals were also calculated for the individual and the summary odds ratios.</p></sec><sec><title>Results</title><sec><title>Own study</title><p>We genotyped three <italic>NAT2 </italic>sequence variations (c.481C&#x0003e;T, c.590G&#x0003e;A and c.857G&#x0003e;A) in 243 healthy unrelated Caucasian control subjects and 124 PD patients. Although the difference in allele frequencies between control and PD was not statistically significant, we observed higher frequencies for <italic>NAT2*4 </italic>[c.481C + c.590G + c.857G] and c.857G&#x0003e;A, and lesser frequencies for c.481C&#x0003e;T and c.590G&#x0003e;A in PD (Table <xref ref-type="table" rid="T1">1</xref>). Sequence variations in PD and control did not deviate from a Hardy-Weinberg equilibrium.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Comparison of <italic>NAT2 </italic>allele frequencies in controls and Parkinson's diseased patients</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center">Allele</td><td align="center" colspan="3">Genetic variations</td><td align="center">Control group (<italic>n </italic>= 243)</td><td align="center">Parkinson's disease (<italic>n </italic>= 124)</td></tr></thead><tbody><tr><td></td><td align="center">c.481C&#x0003e;T</td><td align="center">c.590G&#x0003e;A</td><td align="center">c.857G&#x0003e;A</td><td></td><td></td></tr><tr><td align="center"><italic>NAT2*4</italic></td><td align="center">C</td><td align="center">G</td><td align="center">G</td><td align="center">22.3 %</td><td align="center">28.9 %</td></tr><tr><td align="center"><italic>C</italic><sup><italic>481</italic></sup><italic>T </italic><sub><italic>a</italic></sub></td><td align="center"><bold>T</bold></td><td align="center">G</td><td align="center">G</td><td align="center">48.9 %</td><td align="center">47.3 %</td></tr><tr><td align="center"><italic>G</italic><sup><italic>590</italic></sup><italic>A </italic><sub><italic>b</italic></sub></td><td align="center">C</td><td align="center"><bold>A</bold></td><td align="center">G</td><td align="center">27.0 %</td><td align="center">21.5 %</td></tr><tr><td align="center"><italic>G</italic><sup><italic>857</italic></sup><italic>A </italic><sub><italic>c</italic></sub></td><td align="center">C</td><td align="center">G</td><td align="center"><bold>A</bold></td><td align="center">1.7 %</td><td align="center">2.3 %</td></tr></tbody></table><table-wrap-foot><p>a) <italic>C</italic><sup><italic>481</italic></sup><italic>T </italic>= <italic>NAT2*5A, *5B, *5F, *5G,*5H, *5I, *6E, *11A, *11B, *12C *14C</italic></p><p>b) <italic>G</italic><sup><italic>590</italic></sup><italic>A </italic>= <italic>NAT2*5E, *5J, *6A, *6B, *6C, *6D, * 6E, *14 D</italic></p><p>c) <italic>G</italic><sup><italic>857</italic></sup><italic>A </italic>= <italic>NAT2*7A, *7B</italic></p></table-wrap-foot></table-wrap><p>The genotype frequencies are shown in Table <xref ref-type="table" rid="T2">2</xref>. Heterozygotes for c.481C&#x0003e;T in control and PD did not vary much, but there tend to be more heterozygous carriers for c.590G&#x0003e;A in PD (Table <xref ref-type="table" rid="T2">2</xref>). Moreover, while homozygotes for c.481C&#x0003e;T did not differ in control and PD, homozygotes for c.590G&#x0003e;A were more frequent in control. A homozygote for c.857G&#x0003e;A was only detected in PD. Further comparison of genotype frequencies indicated a two-fold increase of [c.590GA + c.857GA] and approximately one third reduction of [c.481CT + c.590GA] carriers in PD. The [c.857GA] genotype was only found in control population, but this represents only one of 243 individuals. Interestingly, 10 of 243 control individuals carried the two variations, [c.590AA + c.857GA], but the distribution of this genotype did not differ between control and PD. Overall, there was little evidence for statistically different distributions of genotypes in PD and control.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p><italic>NAT2 </italic>genotypes in controls and patients with Parkinson's disease</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="center" colspan="3">Genotypes</td><td align="center">Deduced phenotypes</td><td align="center" colspan="2">Controls</td><td align="center" colspan="2">Parkinson's disease</td><td align="center">Odds ratios (95% confidence interval)</td><td align="center">&#x003c7;<sup>2</sup></td></tr><tr><td colspan="3"/><td></td><td colspan="4"/><td></td><td></td></tr><tr><td align="center">c.481 C&#x0003e;T</td><td align="center">c.590 G&#x0003e;A</td><td align="center">c.857 G&#x0003e;A</td><td></td><td align="center"><italic>n </italic>= 243</td><td align="center">95% CI</td><td align="center"><italic>n </italic>= 124</td><td align="center">95% CI</td><td></td><td></td></tr></thead><tbody><tr><td align="center">CC</td><td align="center">GG</td><td align="center">GG</td><td align="center">rapid</td><td align="center">5.4 % (13)</td><td align="center">2.9 &#x02013; 9.0</td><td align="center">9.7 % (12)</td><td align="center">5.1 &#x02013; 16.3</td><td align="center">1.90 (0.85&#x02013;4.25)</td><td align="center">NS</td></tr><tr><td align="center">CT</td><td></td><td></td><td align="center">rapid</td><td align="center">23.0 % (56)</td><td align="center">17.9&#x02013;28.9</td><td align="center">25.0 % (31)</td><td align="center">17.7 &#x02013; 33.6</td><td align="center">1.11 (0.67&#x02013;1.84)</td><td align="center">NS</td></tr><tr><td></td><td align="center">GA</td><td></td><td align="center">rapid</td><td align="center">8.6 % (21)</td><td align="center">5.4 &#x02013; 12.9</td><td align="center">15.3 % (19)</td><td align="center">9.5 &#x02013; 22.9</td><td align="center">1.91 (0.99&#x02013;3.68)</td><td align="center">p &#x0003c; 0.01</td></tr><tr><td></td><td></td><td align="center">GA</td><td align="center">rapid</td><td align="center">0.4 % (1)</td><td align="center">0.01 &#x02013; 2.3</td><td align="center">ND</td><td align="center">0.0 &#x02013; 2.9</td><td align="center">0.000*</td><td align="center">NS</td></tr><tr><td align="center">TT</td><td></td><td></td><td align="center">slow<sup>1</sup></td><td align="center">22.2 % (54)</td><td align="center">17.2 &#x02013; 28.0</td><td align="center">20.2 % (25)</td><td align="center">13.5 &#x02013; 28.3</td><td align="center">0.88 (0.52&#x02013;1.51)</td><td align="center">NS</td></tr><tr><td></td><td align="center">AA</td><td></td><td align="center">slow</td><td align="center">9.5 % (23)</td><td align="center">6.1 &#x02013; 13.9</td><td align="center">5.7 % (7)</td><td align="center">2.3 &#x02013; 11.3</td><td align="center">0.57 (0.24&#x02013;1.36)</td><td align="center">NS</td></tr><tr><td></td><td align="center">AA</td><td align="center">GA</td><td align="center">slow</td><td align="center">4.1 % (10)</td><td align="center">2.0 &#x02013; 7.4</td><td align="center">3.2 % (4)</td><td align="center">0.9 &#x02013; 8.1</td><td align="center">0.78 (0.24&#x02013;2.53)</td><td align="center">NS</td></tr><tr><td align="center">CT</td><td align="center">GA</td><td></td><td align="center">slow</td><td align="center">23.9 % (58)</td><td align="center">18.7 &#x02013; 29.7</td><td align="center">17.0 % (21)</td><td align="center">10.8 &#x02013; 24.7</td><td align="center">0.65 (0.37&#x02013;1.13)</td><td align="center">NS</td></tr><tr><td align="center">CT</td><td></td><td align="center">GA</td><td align="center">slow</td><td align="center">2.5 % (6)</td><td align="center">0.9 &#x02013; 5.3</td><td align="center">2.4 % (3)</td><td align="center">0.5 &#x02013; 6.9</td><td align="center">0.98 (0.24&#x02013;3.99)</td><td align="center">NS</td></tr><tr><td></td><td align="center">GA</td><td align="center">GA</td><td align="center">slow</td><td align="center">0.4 % (1)</td><td align="center">0.01 &#x02013; 2.3</td><td align="center">0.8 % (1)</td><td align="center">0.02 &#x02013; 4.4</td><td align="center">1.97 (0.13&#x02013;30.24)</td><td align="center">NS</td></tr><tr><td></td><td></td><td align="center">AA</td><td align="center">slow</td><td align="center">ND</td><td align="center">0.0 &#x02013; 1.5</td><td align="center">0.8 % (1)</td><td align="center">0.02 &#x02013; 4.4</td><td align="center">*</td><td align="center">NS</td></tr></tbody></table><table-wrap-foot><p><sup>*</sup>The confidence intervals for the percentages were computed according to Pearson-Clopper, whereas confidence intervals for the odds ratios were computed assuming asymptotic log normality. To avoid undefined results, some estimates were not computed. </p><p><sup>1 </sup>c.481 C&#x0003e;T is a silent mutation associated also with NAT2*12C (c.481 C&#x0003e;T, c.803A&#x0003e;G) and which is a rapid allele (see Hein et al. [7] ) </p></table-wrap-foot></table-wrap></sec><sec><title>Meta-analysis</title><p>We found 13 original published association studies dealing with <italic>NAT2 </italic>gene polymorphisms in Parkinson's disease (see Background). Several studies were undertaken on white Caucasians, but there were also studies on Nigerian Africans [<xref ref-type="bibr" rid="B16">16</xref>], Hongkong Chinese [<xref ref-type="bibr" rid="B12">12</xref>], and Indians [<xref ref-type="bibr" rid="B13">13</xref>]. From these studies, a total of 1,961 cases and 2,433 control subjects have been analyzed for disease association between PD and <italic>NAT2 </italic>genetic variations. If we include our own study cohorts, the overall total would add up to 2,085 PD cases and 2,676 control subjects.</p><p>We summarized published information concerning characteristics of PD patients and control subjects (Table <xref ref-type="table" rid="T3">3</xref>) as well as genetic and disease association analyses (Table <xref ref-type="table" rid="T4">4</xref>) in 11 studies carried out from 1998&#x02013;2005. Studies consisted of one 100% familial, three familial/sporadic and seven sporadic cases, and were either population or hospital-based. Average % male in PD cases was 59% (34&#x02013;74%), while in control 53% (35&#x02013;75%); average age at onset (AAO) was 64 (32&#x02013;77 yr). Three studies stratified AAO into early onset (EOPD, &#x0003c;40 or &#x0003c;50 yr) and late onset (LOPD, &#x0003e;40 or &#x0003e;50 yr). Average age of exam (AAE) for PD cases was available for three studies (average 69 yr) and for control in 10 studies (average 63 yr, range 34&#x02013;74). PD cases were diagnosed through manifestation of &#x0003e;2 cardinal features of PD (e.g. resting tremor, bradykinesia, postural disturbances, absence of and no apparent cause of parkinsonism, and/ or positive response to levodopa therapy). Control subjects were healthy family members, or randomly recruited healthy individuals from the same region, or in one case, pathologically normal brains from a brain bank. In two studies, control subjects were age-matched and in one study, 5&#x02013;10 years older than the PD cases.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Characteristics of studies on <italic>NAT2 </italic>polymorphisms and Parkinson's disease: patients and control subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Authors, country</td><td align="left">Ethnicity of participants</td><td align="left" colspan="6"><bold>PD</bold></td><td align="left" colspan="4"><bold>Control</bold></td></tr><tr><td></td><td></td><td colspan="10"><hr></hr></td></tr><tr><td></td><td></td><td align="left">Source</td><td align="center">Type of PD cases</td><td align="center"><italic>N</italic></td><td align="center">Male sex %</td><td align="center">Age at onset (yr)</td><td align="left">Diagnostic criteria</td><td align="left">Source</td><td align="center"><italic>N</italic></td><td align="center">Age at exam (yr)</td><td align="center">Male sex %</td></tr></thead><tbody><tr><td align="left">Van der Walt et al. 2003, USA</td><td align="left">NG<sup>1</sup></td><td align="left">DCHG Morris Udall PD Cntr., DCHG/Glaxo-Smith Kline PD Genetics Collaboration</td><td align="center">familial</td><td align="center">397 families 607 affected indvls.</td><td align="center">59</td><td align="center">62 &#x000b1; 13 EOPD: &#x02264; 40 LOPD:&#x0003e; 40 AAE: 67 &#x000b1; 12</td><td align="left">levodopa therapy, absence of parkin mutations</td><td align="left">healthy members of affected families</td><td align="center">872 indvls.</td><td align="center">67 &#x000b1; 12</td><td align="center">45</td></tr><tr><td align="left">Bandmann et al. 1997, 2000, UK</td><td align="left">Caucasian</td><td align="left">UK PD Brain Bank, Inst. Psychiatry, London</td><td align="center">familial, sporadic</td><td align="center">100 familial 100 sporadic</td><td align="center">55 familial 65 sporadic</td><td align="center">68.4 &#x000b1; 7.7 (51&#x02013;85) age at death (sporadic): 76.7 &#x000b1; 7.9 (51&#x02013;94)</td><td align="left">criteria, Maraganore et al. 1991<sup>2</sup></td><td align="left">UK PD Brain Bank, normal brains</td><td align="center">100</td><td align="center">77.1 &#x000b1; 8.8 (60&#x02013;90)</td><td align="center">65</td></tr><tr><td align="left">Nicholl et al. 1999, UK</td><td align="left">Caucasian</td><td align="left">West Midlands Region, UK</td><td align="center">familial, sporadic</td><td align="center">30 familial 176 sporadic</td><td align="center">57 familial 60 sporadic</td><td align="center">63.9 familial 64.5 sporadic</td><td align="left">response to levodopa or dopamine agonists, = 2 cardinal PD features</td><td align="left">hospitals in two separate regions within the UK West Midlands</td><td align="center">30 familial 176 sporadic</td><td align="center">63.9 familial 63 sporadic</td><td align="center">57 familial 60 sporadic</td></tr><tr><td align="left">Chaudhary et al. 2005, India</td><td align="left">Indian</td><td align="left">two hospitals: New Delhi, Bangalore</td><td align="center">sporadic</td><td align="center">267</td><td align="center">74 EOPD: 69 LOPD: 79</td><td align="center">31.8 &#x000b1; 8.5 EOPD : &#x02264; 40 52.35 &#x000b1; 9.0 LOPD:&#x0003e; 40</td><td align="left">criteria, UK PD Brain Bank</td><td align="left">healthy spouses of PD subjects, outpatient dept participating hospitals</td><td align="center">324</td><td align="center">45.83 &#x000b1; 2.88 EOPD control 64.04 &#x000b1; 8.13 LOPD control</td><td align="center">75 EOPD control 74 LOPD control</td></tr><tr><td align="left">Chan et al. 2003, China</td><td align="left">Hongkong Chinese</td><td align="left">two hospitals, Hongkong</td><td align="center">sporadic</td><td align="center">99</td><td align="center">60</td><td align="center">71.7 (46&#x02013;93) 4 patients &#x02264; 45</td><td align="left">criteria, Maraganore et al. 1991<sup>2</sup>, levodopa therapy</td><td align="left">same hospitals as PD cases</td><td align="center">126</td><td align="center">70.2 (39&#x02013;96)</td><td align="center">50</td></tr><tr><td align="left">Bialecka et al. 2002, Poland</td><td align="left">Caucasian</td><td align="left">Pomeranian region</td><td align="center">sporadic</td><td align="center">54</td><td align="center">NG<sup>1</sup></td><td align="center">68</td><td align="left">= 2 cardinal PD features</td><td align="left">same region, randomly selected</td><td align="center">85</td><td align="center">73.4 &#x000b1; 5.8(65&#x02013;87)</td><td align="center">NG<sup>1</sup></td></tr><tr><td align="left">Maraganore et al. 2000, USA</td><td align="left">Caucasian (almost)</td><td align="left">Mayo Clinic referrals (from MN, WI, ND, SD) and PD study Olmsted County, MN</td><td align="center">sporadic</td><td align="center">139</td><td align="center">65</td><td align="center">62 (31&#x02013;82) AAE: 69 (39&#x02013;91)</td><td align="left">= 2 cardinal PD features, levodopa therapy</td><td align="left">Olmsted County, MN, healthy spouses of PD subjects</td><td align="center">113</td><td align="center">72 (37&#x02013;90)</td><td align="center">35</td></tr><tr><td align="left">Dupret et al. 1999, France</td><td align="left">Caucasian</td><td align="left">hospitals and clinics in Champagne-Ardenne</td><td align="center">sporadic</td><td align="center">68</td><td align="center">67</td><td align="center">61 &#x000b1; 9 (25&#x02013;88) AAE: 71 &#x000b1; 9</td><td align="left">cardinal PD features</td><td align="left">same region as PD cases</td><td align="center">211</td><td align="center">43.8 &#x000b1; 6.1</td><td align="center">50</td></tr><tr><td align="left">Harhangi et al. 1999, Netherlands</td><td align="left">Caucasian</td><td align="left">PD cases in Rotterdam</td><td align="center">sporadic</td><td align="center">80</td><td align="center">34</td><td align="center">77.3 &#x000b1; 8.3 (57&#x02013;99)</td><td align="left">= 2 cardinal PD features</td><td align="left">same region as PD cases</td><td align="center">161</td><td align="center">78 &#x000b1; 8.3 (57&#x02013;98)</td><td align="center">39</td></tr><tr><td align="left">Agundez et al. 1998, Spain</td><td align="left">Caucasian</td><td align="left">hospitals in Madrid and vicinity</td><td align="center">sporadic</td><td align="center">121</td><td align="center">EOPD: 54 LOPD: 52</td><td align="center">41.3 &#x000b1; 6.4 (28&#x02013;50) OEPD: 28&#x02013;50 67.3 &#x000b1; 8.2 (51&#x02013;83) LOPD : &#x0003e;51</td><td align="left">criteria, Hughes et al. 1992<sup>3</sup></td><td align="left">volunteers from the same region</td><td align="center">121</td><td align="center">34.2 &#x000b1; 12.5</td><td align="center">53</td></tr></tbody></table><table-wrap-foot><p><sup>1</sup>NG =not given </p><p><sup> 2</sup> Maraganore DM, Harding AE, Marsden CD. A clinical and genetic study of familial Parkinson's disease. Mov Disord 1991; 6:205-211. </p><p><sup>3 </sup>Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55:181-184. </p></table-wrap-foot></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Characteristics of studies on <italic>NAT2 </italic>polymorphisms and Parkinson's disease: genetic and disease-association analyses</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Authors, country</td><td align="center">Samples</td><td align="left"><italic>NAT2 </italic>variants</td><td align="left">Assay</td><td align="left">Statistical analysis</td><td align="center">Slow acetylator PD cases (%)</td><td align="center">Slow acetylator controls (%)</td><td align="left">Association Yes/No</td></tr></thead><tbody><tr><td align="left">Van der Walt et al. 2003, USA</td><td align="center">blood</td><td align="left">282, 341,481,590, 857</td><td align="left">oligo ligation assay</td><td align="left">pedigree disequilibrium test (PDT-sum), likelihood ratio test (Transmit), &#x003c7;<sup>2</sup>-test</td><td align="center">NG<sup>1</sup></td><td align="center">NG<sup>1</sup></td><td align="left">No overall, but marginal c.282 in EOPD</td></tr><tr><td align="left">Bandmann et al. 2000, UK</td><td align="center">blood, brain tissue</td><td align="left">191, 341,282,481,590, 803, 857</td><td align="left">allele-specific CR, PCR-RFLP</td><td align="left">&#x003c7;<sup>2</sup>-test, OR 95% CI, Yate's correction</td><td align="center">familial: 69.0 sporadic: 59.0</td><td align="center">37.0</td><td align="left">Yes</td></tr><tr><td align="left">Bandmann et al. 1997, UK</td><td align="center">blood, brain tissue</td><td align="left">481, 590, 857</td><td align="left">PCR-RFLP</td><td align="left">&#x003c7;<sup>2</sup>-test, OR 95% CI, Yate's correction</td><td align="center">familial: 73 sporadic: 60</td><td align="center">39.0</td><td align="left">Yes</td></tr><tr><td align="left">Nicholl et al. 1999, UK</td><td align="center">blood</td><td align="left">481, 282, 590, 803, few cases: 191, 857</td><td align="left">PCR-RFLP</td><td align="left">&#x003c7;<sup>2</sup>-test, two-sample <italic>t- </italic>or Wilcoxon tests, OR 95% CI</td><td align="center">familial: 53.3 sporadic: 60.1</td><td align="center">familial: 76.7 sporadic: 55.4</td><td align="left">No</td></tr><tr><td align="left">Chaudhary et al. 2005, India</td><td align="center">blood</td><td align="left">191, 282, 341,481, 590, 803, 857</td><td align="left">PCR-RFLP</td><td align="left">&#x003c7;<sup>2</sup>-test, PHASE 2.0.2 for haplotypes, OR 95% CI</td><td align="center">pooled: 19.2 EOPD: 25.78 LOPD: 12.29</td><td align="center">pooled: 13.45 EOPD control: 13.01 LOPD control: 13.78</td><td align="left">Yes, c.590 and c.857 in EOPD c.282 in LOPD</td></tr><tr><td align="left">Chan et al. 2003, China</td><td align="center">blood</td><td align="left">481,590,857</td><td align="left">PCR-RFLP</td><td align="left">logistic regression analysis, adjusted OR 95% CI</td><td align="center">68.7</td><td align="center">28.6</td><td align="left">Yes</td></tr><tr><td align="left">Bialecka et al. 2002, Poland</td><td align="center">blood</td><td align="left">481,590,803,857</td><td align="left">PCR-RFLP</td><td align="left">&#x003c7;<sup>2</sup>-test, OR 95% CI, Yate's correction</td><td align="center">64.8</td><td align="center">46.9</td><td align="left">Yes</td></tr><tr><td align="left">Maraganore et al. 2000, USA</td><td align="center">blood</td><td align="left">481,590, 857</td><td align="left">PCR-RFLP</td><td align="left">logistic regression analysis, adjusted OR 95% CI, two-sided <italic>p </italic>values</td><td align="center">54.0</td><td align="center">53.0</td><td align="left">No overall, but c.857</td></tr><tr><td align="left">Dupret et al. 1999, France</td><td align="center">blood</td><td align="left">191,341,590,857</td><td align="left">allele-specific PCR, PCR-RFLP</td><td align="left">NG<sup>1</sup></td><td align="center">51.5</td><td align="center">59.8</td><td align="left">No</td></tr><tr><td align="left">Harhangi et al. 1999, Netherlands</td><td align="center">blood</td><td align="left">481,590, 857</td><td align="left">PCR-RFLP</td><td align="left">OR 95% CI, Fischer's exact test two tailed</td><td align="center">54.0</td><td align="center">53.0</td><td align="left">No</td></tr><tr><td align="left">Agundez et al. 1998, Spain</td><td align="center">blood</td><td align="left">191, 282, 341, 590, 803, 857</td><td align="left">PCR-RFLP</td><td align="left">&#x003c7;<sup>2</sup>-test, OR 95% CI, Fischer's exact test</td><td align="center">EOPD: 78.4 LOPD: 54.8</td><td align="center">55.4</td><td align="left">No overall, but yes OEPD</td></tr></tbody></table><table-wrap-foot><p>NG<sup>1</sup>=not given</p></table-wrap-foot></table-wrap><p>Genomic DNA from blood samples was used in all studies but one, and PCR-RFLP was mainly the method employed for genotyping analysis. All studies basically analyzed the <italic>NAT2 </italic>variants c.481C&#x0003e;T, 590G&#x0003e;A, 857G&#x0003e;A and in all, the variant c.590G&#x0003e;A. Disease association was determined generally by computing odds ratios, except for a family-based study in which pedigree disequilibrium (PDT) or likelihood ratio (Transmit) tests were used [<xref ref-type="bibr" rid="B20">20</xref>]. Either there was overall association of slow acetylator genotypes to PD [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B12">12</xref>], or there was no overall association [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B18">18</xref>-<xref ref-type="bibr" rid="B20">20</xref>]. In addition, two earlier studies did not also find association between slow acetylator genotypes and PD [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. Some studies, however, found positive association of certain variants (e.g. c.857G&#x0003e;A, [<xref ref-type="bibr" rid="B18">18</xref>], in particular to early-onset PD [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B13">13</xref>].</p><p>To obtain synthesis of data from multiple studies, we have undertaken a meta-analysis of slow acetylators in PD vs. control subjects in 10 studies including our own (Fig. <xref ref-type="fig" rid="F1">1A</xref>). Only data on sporadic cases were included. The odds ratios were significantly different between the studies (p = 2.89334e-07), and were consistent with respective authors' conclusions. For the pooled analysis of 604/1206 PD vs. 732/1619 control subjects, we obtained a Mantel-Haenszel OR of 1.32 (95% CI 1.12&#x02013;1.54) which was significantly greater than 1 (p &#x0003c; 0.05). Because the studies of Bandmann et al. 2000 [<xref ref-type="bibr" rid="B10">10</xref>], and Chan et al. 2003 [<xref ref-type="bibr" rid="B12">12</xref>] were the only ones showing positive association of slow acetylators to PD, excluding these investigations resulted in a non-significant OR (1.07, 95% CI 0.9&#x02013;1.28) (Fig. <xref ref-type="fig" rid="F1">1B</xref>). Our own study appeared to show an inverse association of slow acetylators to PD (OR 0.60, 95% CI 0.39&#x02013;0.93, based on 62/124 PD vs.152/243 controls), but the ORs in Fig. <xref ref-type="fig" rid="F1">1B</xref> did not differ significantly between each other.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Meta-analysis of association studies on <italic>NAT2 </italic>slow acetylators and sporadic Parkinson's disease. </bold>The confidence interval for each study is given by a horizontal line, and the point estimate is given by a square whose height is inversely proportional to the standard error of the estimate. The summary odds ratio is drawn as a diamond with horizontal limits at the confidence limits and width inversely proportional to its standard error. <bold>(A)</bold>: Meta-analysis on 10 studies. Test for heterogeneity &#x003c7;<sup>2 </sup>(df 9) = 47.71 (p-value 0). The odds ratios are significantly different between the studies. The summary odds ratio (Mantel-Haenszel OR= 1.32, 95% CI, 1.12&#x02013;1.54) is significantly greater than 1 (p &#x0003c; 0.05). <bold>(B) </bold>Meta-analysis on 8 studies, excluding studies of Bandmann et al. 2000 and Chan et al. 2003. The odds ratios are not significantly different between studies. Test for heterogeneity &#x003c7;<sup>2 </sup>(df 7) = 14.28 (p = 0.0464). The summary odds ratio (OR= 1.07, 95% CI, 0.9&#x02013;1.28) is not significant.</p></caption><graphic xlink:href="1471-2350-7-30-1"/></fig><p>Furthermore, our analysis of five studies for c.590G&#x0003e;A comparing the allele frequency A in PD vs. control subjects found that odds ratios were not significantly different between the studies (p = 0.67) (Fig. <xref ref-type="fig" rid="F2">2</xref>). The summary OR= 0.94 (95% CI, 0.79&#x02013;1.12) did not deviate significantly from 1. Similarly, analysis of four studies for the genotype c.590AA did not find significant differences between studies, and the summary OR = 1.06 (95% CI, 0.78&#x02013;1.43) was likewise not significant (Fig. <xref ref-type="fig" rid="F2">2</xref>).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>Meta-analysis of <italic>NAT2 </italic>c.590G&#x0003e;A in PD and control subjects. </bold>The confidence interval for each study is given by a horizontal line, and the point estimate is given by a square whose height is inversely proportional to the standard error of the estimate. The summary odds ratio is drawn as a diamond with horizontal limits at the confidence limits and width inversely proportional to its standard error. Allele frequency: Test for heterogeneity &#x003c7;<sup>2 </sup>(df 4) = 2.36 (p-value 0.67). The odds ratios are not significantly different between the studies (p = 0.67). The summary odds ratio (Mantel-Haenszel OR= 0.94, 95% CI, 0.79&#x02013;1.12) is not significantly greater than 1 (p &#x0003e; 0.05). Genotype frequency: Test for heterogeneity &#x003c7;<sup>2 </sup>(df 3) = 9.58 (p-value 0.0225). The odds ratios are not significantly different between the studies (p = 0.0225). The summary odds ratio (Mantel-Haenszel OR= 0.94, 95% CI, 0.78&#x02013;1.43) not significantly different from 1.</p></caption><graphic xlink:href="1471-2350-7-30-2"/></fig></sec></sec><sec><title>Discussion</title><p>Overall, we demonstrate little evidence for differences in polymorphic acetylation genotypes when a control and Parkinson's diseased population is compared. This finding may contrasts previous studies, but is similar to results of other studies on Caucasians where no overall association has been found (see Meta-analysis, Results). For instance, one study found a strong association between slow acetylator genotypes and familial PD (<italic>n </italic>= 100) in European patients [<xref ref-type="bibr" rid="B10">10</xref>]. Another study found a statistically significant predominance of slow acetylators in sporadic PD (<italic>n </italic>= 54) in Polish population [<xref ref-type="bibr" rid="B11">11</xref>]. In unrelated Hongkong Chinese with PD (<italic>n </italic>= 99), a strong association between <italic>NAT2 </italic>genotypes and PD was likewise found [<xref ref-type="bibr" rid="B12">12</xref>]. Recently, in an Indian population, a significant association was found for c.590G&#x0003e;A and 857G&#x0003e;A in early-onset, as well as c.282C&#x0003e;T in late-onset PD [<xref ref-type="bibr" rid="B13">13</xref>].</p><p>Nonetheless, there are also studies which do not show association between <italic>NAT2 </italic>genotypes and PD. For instance, no statistically significant differences were found after comparison of <italic>NAT2 </italic>genotypes between sporadic PD (<italic>n </italic>= 121) and control group [<xref ref-type="bibr" rid="B8">8</xref>]. They observed, however, that patients with early-onset PD (before 50 years, <italic>n </italic>= 37), displayed a higher frequency of slow acetylator types. Further, Dupret et al. [<xref ref-type="bibr" rid="B14">14</xref>] found similar distribution of slow acetylators in sporadic French PD (<italic>n </italic>= 68) and control. Harhangi et al. [<xref ref-type="bibr" rid="B15">15</xref>] found likewise that overall frequencies were distributed similarly among PD (<italic>n </italic>= 132) patients and control. Of considerable importance is the finding of a recent family-based study which analyzed 397 families (<italic>n </italic>= 1580 individuals, 607 affected) and found no overall association between any <italic>NAT2 </italic>genetic variations (single or combined) and familial or early-onset PD [<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Our meta-analysis of 10 studies of slow acetylators representing data from 1,206 PD patients and 1,619 control subjects gave an OR value of 1.32 (95% CI 1.12&#x02013;1.54) which was marginally significant (p &#x0003c; 0.05). This result is similar to an earlier meta-analysis where a total of 792 PD patients and 912 control subjects from seven studies published between 1989&#x02013;1999 were investigated. Specifically, the frequency of slow to rapid acetylator genotypes for the composite seven studies showed a significant association of patients with PD to control subjects (OR = 1.33; 95% CI, 1.08 to 1.62) [<xref ref-type="bibr" rid="B23">23</xref>]. However, our meta-analysis on eight studies, omitting the studies of Bandmann et al. 2000 [<xref ref-type="bibr" rid="B10">10</xref>] and Chan et al. 2003 [<xref ref-type="bibr" rid="B12">12</xref>], resulted in an OR of 1.07, 95% CI 0.9&#x02013;1.28, which was not significant. This result shows that these two studies were solely responsible for the marginal positive association obtained in the meta-analysis of 10 studies. Indeed, the inclusion of Chan et al. 2000 [<xref ref-type="bibr" rid="B12">12</xref>] in a meta-analysis of nine studies would still give an OR of 1.25, 95% CI, 1.06&#x02013;1.47, and p &#x0003c;0.05. Although our study appeared to show an inverse association of slow acetylators to PD (OR 0.60, 95% CI 0.39&#x02013;0.93), this OR did not differ significantly from other studies (see Fig. <xref ref-type="fig" rid="F1">1B</xref>).</p><p>Furthermore, our analysis of five studies for c.590G&#x0003e;A comparing the allele frequency A in 473 PD vs. 620 control subjects found that the summary OR 0.94 (95% CI, 0.79&#x02013;1.12) did not deviate significantly from 1. Similarly, the odds ratios in four studies for the genotype c.590AA was not different from each other and the obtained OR value (OR = 1.06, 95% CI 0.78&#x02013;1.43) was not significantly different from 1. Therefore, there appears to be no overall association of slow acetylator genotypes to PD.</p><p>Our systematic review and meta-analysis of <italic>NAT2 </italic>studies on PD could serve as an initial assessment or synthesis of studies towards understanding of the specific role of <italic>NAT2 </italic>acetylation variants in PD. As reflected in the summary of <italic>NAT2 </italic>studies and PD (see Tables <xref ref-type="table" rid="T3">3</xref> and <xref ref-type="table" rid="T4">4</xref>), there is lack of uniformity in study design as well as in the genetic analysis and interpretation of results. Such difficulties and confusions regarding <italic>NAT2 </italic>studies and PD have been outlined earlier [<xref ref-type="bibr" rid="B24">24</xref>]. For instance, in some studies there was no report on genotype frequencies or studies have different focal emphasis, i.e. familial or sporadic PD. To determine specifically the role of <italic>NAT2 </italic>acetylation variants in PD, perhaps a collaborative effort is needed with uniform study design involving different ethnic groups as has been demonstrated in the meta-analysis of <italic>UCHL1 </italic>studies in PD [<xref ref-type="bibr" rid="B3">3</xref>].</p></sec><sec><title>Conclusion</title><p>Overall, our study did not find significant differences in polymorphic acetylation genotypes in PD and control subjects. The meta-analysis on 10 studies showed a marginal positive association of slow acetylators to PD, but this result was driven by two studies, the exclusion of which in the re-analysis provided a non-significant estimate. Apparently, there appears to be no overall association of <italic>NAT2 </italic>slow acetylator genotypes to Parkinson's disease.</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>JB was responsible for the conception and design, acquisition and analysis of data, interpretation of results and writing of the manuscript, and have given final approval of the version to be published. SMRB participated in the conception and design, acquisition and analysis of data, interpretation of results and writing of the manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2350/7/30/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>This study was supported by the Ministry of Science and Culture, Lower Saxony, Germany; Grant number: 25A.5-7251-99-3/00. We thank Prof. H. Hecker, Institute of Biometrics, Medical School Hannover for the statistical analysis.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>TT</given-names></name><name><surname>Schapira</surname><given-names>AH</given-names></name></person-group><article-title>Genetic and environmental factors in the cause of Parkinson's disease</article-title><source>Ann Neurol</source><year>2003</year><volume>53</volume><fpage>S16</fpage><lpage>S23</lpage><pub-id pub-id-type="pmid">12666095</pub-id><pub-id pub-id-type="doi">10.1002/ana.10487</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>de Andrade</surname><given-names>M</given-names></name><name><surname>Lesnick</surname><given-names>TG</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Bower</surname><given-names>JH</given-names></name><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name></person-group><article-title>Complex interactions in Parkinson's disease: a two-phased approach</article-title><source>Mov Disord</source><year>2003</year><volume>18</volume><fpage>631</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">12784265</pub-id><pub-id pub-id-type="doi">10.1002/mds.10431</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>Lesnick</surname><given-names>TG</given-names></name><name><surname>Elbaz</surname><given-names>A</given-names></name><name><surname>Chartier-Harlin</surname><given-names>MC</given-names></name><name><surname>Gasser</surname><given-names>T</given-names></name><name><surname>Kruger</surname><given-names>R</given-names></name><name><surname>Hattori</surname><given-names>N</given-names></name><name><surname>Mellick</surname><given-names>GD</given-names></name><name><surname>Quattrone</surname><given-names>A</given-names></name><name><surname>Satoh</surname><given-names>J</given-names></name><name><surname>Toda</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name><name><surname>de Andrade</surname><given-names>M</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name></person-group><article-title>UCHL1 is a Parkinson's disease susceptibility gene</article-title><source>Ann Neurol</source><year>2004</year><volume>55</volume><fpage>512</fpage><lpage>521</lpage><pub-id pub-id-type="pmid">15048890</pub-id><pub-id pub-id-type="doi">10.1002/ana.20017</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nagatsu</surname><given-names>T</given-names></name></person-group><article-title>Amine-related neurotoxins in Parkinson's disease: past, present, and future</article-title><source>Neurotoxicol Teratol</source><year>2002</year><volume>24</volume><fpage>565</fpage><lpage>569</lpage><pub-id pub-id-type="pmid">12200187</pub-id><pub-id pub-id-type="doi">10.1016/S0892-0362(02)00209-X</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Butcher</surname><given-names>NJ</given-names></name><name><surname>Boukouvala</surname><given-names>S</given-names></name><name><surname>Sim</surname><given-names>E</given-names></name><name><surname>Minchin</surname><given-names>RF</given-names></name></person-group><article-title>Pharmacogenetics of the arylamine N-acetyltransferases</article-title><source>Pharmacogenomics</source><year>2002</year><volume>2</volume><fpage>30</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1038/sj.tpj.6500053</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grant</surname><given-names>DM</given-names></name><name><surname>Goodfellow</surname><given-names>GH</given-names></name><name><surname>Sugamori</surname><given-names>K</given-names></name><name><surname>Durette</surname><given-names>K</given-names></name></person-group><article-title>Pharmacogenetics of the human arylamine N-acetyltransferases</article-title><source>Pharmacology</source><year>2000</year><volume>61</volume><fpage>204</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">10971207</pub-id><pub-id pub-id-type="doi">10.1159/000028402</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hein</surname><given-names>DW</given-names></name><name><surname>Doll</surname><given-names>MA</given-names></name><name><surname>Fretland</surname><given-names>AJ</given-names></name><name><surname>Leff</surname><given-names>MA</given-names></name><name><surname>Webb</surname><given-names>SJ</given-names></name><name><surname>Xiao</surname><given-names>GH</given-names></name><name><surname>Devanaboyina</surname><given-names>US</given-names></name><name><surname>Nangju</surname><given-names>NA</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name></person-group><article-title>Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2000</year><volume>9</volume><fpage>29</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">10667461</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Agundez</surname><given-names>JA</given-names></name><name><surname>Jimenez-Jimenez</surname><given-names>FJ</given-names></name><name><surname>Luengo</surname><given-names>A</given-names></name><name><surname>Molina</surname><given-names>JA</given-names></name><name><surname>Orti-Pareja</surname><given-names>M</given-names></name><name><surname>Vazquez</surname><given-names>A</given-names></name><name><surname>Ramos</surname><given-names>F</given-names></name><name><surname>Duarte</surname><given-names>J</given-names></name><name><surname>Coria</surname><given-names>F</given-names></name><name><surname>Ladero</surname><given-names>JM</given-names></name><name><surname>Alvarez-Cermeno</surname><given-names>JC</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name></person-group><article-title>Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease</article-title><source>Neurology</source><year>1998</year><volume>51</volume><fpage>1587</fpage><lpage>1592</lpage><pub-id pub-id-type="pmid">9855506</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bandmann</surname><given-names>O</given-names></name><name><surname>Vaughan</surname><given-names>J</given-names></name><name><surname>Holmans</surname><given-names>P</given-names></name><name><surname>Marsden</surname><given-names>CD</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group><article-title>Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease</article-title><source>Lancet</source><year>1997</year><volume>350</volume><fpage>1136</fpage><lpage>1139</lpage><pub-id pub-id-type="pmid">9343502</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(97)03495-8</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bandmann</surname><given-names>O</given-names></name><name><surname>Vaughan</surname><given-names>JR</given-names></name><name><surname>Holmans</surname><given-names>P</given-names></name><name><surname>Marsden</surname><given-names>CD</given-names></name><name><surname>Wood</surname><given-names>NW</given-names></name></person-group><article-title>Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease</article-title><source>Mov Disord</source><year>2000</year><volume>15</volume><fpage>30</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">10634239</pub-id><pub-id pub-id-type="doi">10.1002/1531-8257(200001)15:1&#x0003c;30::AID-MDS1007&#x0003e;3.0.CO;2-V</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bialecka</surname><given-names>M</given-names></name><name><surname>Gawronska-Szklarz</surname><given-names>B</given-names></name><name><surname>Drozdzik</surname><given-names>M</given-names></name><name><surname>Honczarenko</surname><given-names>K</given-names></name><name><surname>Stankiewicz</surname><given-names>J</given-names></name></person-group><article-title>N-acetyltransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population</article-title><source>Eur J Clin Pharmacol</source><year>2002</year><volume>57</volume><fpage>857</fpage><lpage>862</lpage><pub-id pub-id-type="pmid">11936704</pub-id><pub-id pub-id-type="doi">10.1007/s00228-001-0415-4</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DK</given-names></name><name><surname>Lam</surname><given-names>MK</given-names></name><name><surname>Wong</surname><given-names>R</given-names></name><name><surname>Hung</surname><given-names>WT</given-names></name><name><surname>Wilcken</surname><given-names>DE</given-names></name></person-group><article-title>Strong association between N-acetyltransferase 2 genotype and PD in Hong Kong Chinese</article-title><source>Neurology</source><year>2003</year><volume>60</volume><fpage>1002</fpage><lpage>1005</lpage><pub-id pub-id-type="pmid">12654968</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaudhary</surname><given-names>S</given-names></name><name><surname>Behari</surname><given-names>M</given-names></name><name><surname>Dihana</surname><given-names>M</given-names></name><name><surname>Swaminath</surname><given-names>PV</given-names></name><name><surname>Govindappa</surname><given-names>ST</given-names></name><name><surname>Jayaram</surname><given-names>S</given-names></name><name><surname>Singh</surname><given-names>S</given-names></name><name><surname>Muthane</surname><given-names>UB</given-names></name><name><surname>Juyal</surname><given-names>RC</given-names></name><name><surname>B K</surname><given-names>T</given-names></name></person-group><article-title>Association of N-acetyl transferase 2 gene polymorphism and slow acetylator phenotype with young onset and late onset Parkinson's disease among Indians</article-title><source>Pharmacogenet Genomics</source><year>2005</year><volume>15</volume><fpage>731</fpage><lpage>735</lpage><pub-id pub-id-type="pmid">16141799</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dupret</surname><given-names>JM</given-names></name><name><surname>Longuemaux</surname><given-names>S</given-names></name><name><surname>Lucotte</surname><given-names>G</given-names></name></person-group><article-title>Acetylator genotype for N-acetyltransferase 2 and Parkinson's disease</article-title><source>Ann Neurol</source><year>1999</year><volume>46</volume><fpage>433</fpage><lpage>434</lpage><pub-id pub-id-type="pmid">10482279</pub-id><pub-id pub-id-type="doi">10.1002/1531-8249(199909)46:3&#x0003c;433::AID-ANA24&#x0003e;3.0.CO;2-H</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Harhangi</surname><given-names>BS</given-names></name><name><surname>Oostra</surname><given-names>BA</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>van Duijn</surname><given-names>CM</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Breteler</surname><given-names>MM</given-names></name></person-group><article-title>N-acetyltransferase-2 polymorphism in Parkinson's disease: the Rotterdam study</article-title><source>J Neurol Neurosurg Psychiatry</source><year>1999</year><volume>67</volume><fpage>518</fpage><lpage>520</lpage><pub-id pub-id-type="pmid">10486401</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Igbokwe</surname><given-names>E</given-names></name><name><surname>Ogunniyi</surname><given-names>AO</given-names></name><name><surname>Osuntokun</surname><given-names>BO</given-names></name></person-group><article-title>Xenobiotic metabolism in idiopathic Parkinson's disease in Nigerian Africans</article-title><source>East Afr Med J</source><year>1993</year><volume>70</volume><fpage>807</fpage><lpage>809</lpage><pub-id pub-id-type="pmid">8026358</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ladero</surname><given-names>JM</given-names></name><name><surname>Jimenez</surname><given-names>FJ</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name><name><surname>Fernandez-Gundin</surname><given-names>MJ</given-names></name><name><surname>Martinez</surname><given-names>C</given-names></name><name><surname>Llerena</surname><given-names>A</given-names></name><name><surname>Cobaleda</surname><given-names>J</given-names></name><name><surname>Munoz</surname><given-names>JJ</given-names></name></person-group><article-title>Acetylator polymorphism in Parkinson's disease</article-title><source>Eur J Clin Pharmacol</source><year>1989</year><volume>37</volume><fpage>391</fpage><lpage>393</lpage><pub-id pub-id-type="pmid">2598972</pub-id><pub-id pub-id-type="doi">10.1007/BF00558506</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Maraganore</surname><given-names>DM</given-names></name><name><surname>Farrer</surname><given-names>MJ</given-names></name><name><surname>Hardy</surname><given-names>JA</given-names></name><name><surname>McDonnell</surname><given-names>SK</given-names></name><name><surname>Schaid</surname><given-names>DJ</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name></person-group><article-title>Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease</article-title><source>Mov Disord</source><year>2000</year><volume>15</volume><fpage>714</fpage><lpage>719</lpage><pub-id pub-id-type="pmid">10928584</pub-id><pub-id pub-id-type="doi">10.1002/1531-8257(200007)15:4&#x0003c;714::AID-MDS1018&#x0003e;3.0.CO;2-3</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nicholl</surname><given-names>DJ</given-names></name><name><surname>Bennett</surname><given-names>P</given-names></name><name><surname>Hiller</surname><given-names>L</given-names></name><name><surname>Bonifati</surname><given-names>V</given-names></name><name><surname>Vanacore</surname><given-names>N</given-names></name><name><surname>Fabbrini</surname><given-names>G</given-names></name><name><surname>Marconi</surname><given-names>R</given-names></name><name><surname>Colosimo</surname><given-names>C</given-names></name><name><surname>Lamberti</surname><given-names>P</given-names></name><name><surname>Stocchi</surname><given-names>F</given-names></name><name><surname>Bonuccelli</surname><given-names>U</given-names></name><name><surname>Vieregge</surname><given-names>P</given-names></name><name><surname>Ramsden</surname><given-names>DB</given-names></name><name><surname>Meco</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>AC</given-names></name></person-group><article-title>A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. European Study Group on Atypical Parkinsonism</article-title><source>Neurology</source><year>1999</year><volume>53</volume><fpage>1415</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">10534244</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Walt</surname><given-names>JM</given-names></name><name><surname>Martin</surname><given-names>ER</given-names></name><name><surname>Scott</surname><given-names>WK</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Nance</surname><given-names>MA</given-names></name><name><surname>Watts</surname><given-names>RL</given-names></name><name><surname>Hubble</surname><given-names>JP</given-names></name><name><surname>Haines</surname><given-names>JL</given-names></name><name><surname>Koller</surname><given-names>WC</given-names></name><name><surname>Lyons</surname><given-names>K</given-names></name><name><surname>Pahwa</surname><given-names>R</given-names></name><name><surname>Stern</surname><given-names>MB</given-names></name><name><surname>Colcher</surname><given-names>A</given-names></name><name><surname>Hiner</surname><given-names>BC</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Ondo</surname><given-names>WG</given-names></name><name><surname>Allen</surname><given-names>FH</given-names><suffix>Jr</suffix></name><name><surname>Goetz</surname><given-names>CG</given-names></name><name><surname>Small</surname><given-names>GW</given-names></name><name><surname>Mastaglia</surname><given-names>F</given-names></name><name><surname>Roses</surname><given-names>AD</given-names></name><name><surname>Stajich</surname><given-names>JM</given-names></name><name><surname>Booze</surname><given-names>MW</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name><name><surname>Gibson</surname><given-names>RA</given-names></name><name><surname>Middleton</surname><given-names>LT</given-names></name><name><surname>Scott</surname><given-names>BL</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name></person-group><article-title>Genetic polymorphisms of the N-acetyltransferase genes and risk of Parkinson's disease</article-title><source>Neurology</source><year>2003</year><volume>60</volume><fpage>1189</fpage><lpage>1191</lpage><pub-id pub-id-type="pmid">12682333</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grundmann</surname><given-names>M</given-names></name><name><surname>Earl</surname><given-names>CD</given-names></name><name><surname>Sautter</surname><given-names>J</given-names></name><name><surname>Henze</surname><given-names>C</given-names></name><name><surname>Oertel</surname><given-names>WH</given-names></name><name><surname>Bandmann</surname><given-names>O</given-names></name></person-group><article-title>Slow N-acetyltransferase 2 status leads to enhanced intrastriatal dopamine depletion in 6-hydroxydopamine-lesioned rats</article-title><source>Exp Neurol</source><year>2004</year><volume>187</volume><fpage>199</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">15081601</pub-id><pub-id pub-id-type="doi">10.1016/j.expneurol.2004.01.001</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cascorbi</surname><given-names>I</given-names></name><name><surname>Drakoulis</surname><given-names>N</given-names></name><name><surname>Brockmoller</surname><given-names>J</given-names></name><name><surname>Maurer</surname><given-names>A</given-names></name><name><surname>Sperling</surname><given-names>K</given-names></name><name><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity</article-title><source>Am J Hum Genet</source><year>1995</year><volume>57</volume><fpage>581</fpage><lpage>592</lpage><pub-id pub-id-type="pmid">7668286</pub-id></citation></ref><ref id="B23"><citation citation-type="other"><source>The R Project for Statistical Computing</source><ext-link ext-link-type="uri" xlink:href="http://www.r-project.org"/></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EK</given-names></name><name><surname>Khajavi</surname><given-names>M</given-names></name><name><surname>Thornby</surname><given-names>JI</given-names></name><name><surname>Nagamitsu</surname><given-names>S</given-names></name><name><surname>Jankovic</surname><given-names>J</given-names></name><name><surname>Ashizawa</surname><given-names>T</given-names></name></person-group><article-title>Variability and validity of polymorphism association studies in Parkinson's disease</article-title><source>Neurology</source><year>2000</year><volume>55</volume><fpage>533</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">10953187</pub-id></citation></ref></ref-list></back></article> 